GlassScriptPhysician profile
Nabeel Sarhill
NPI 1811098304
$3,777.15
in general payments reported to CMS, 2019-2025
44 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $18.00 · 2021: $62.67 · 2022: $671 · 2023: $1,091 · 2024: $971 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136 · Education: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.43 |
| Education | $762.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $375.50 | 2022-2025 | Vyloy, Xospata |
| Seagen INC. | $237.99 | 2022-2023 | Padcev, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $237.73 | 2022-2024 | Opdivo |
| Celgene Corporation | $201.27 | 2022-2025 | Reblozyl, Pomalyst |
| Boston Scientific Corporation | $191.93 | 2022-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Eisai INC. | $184.51 | 2022-2025 | |
| Pfizer INC. | $183.54 | 2022-2025 | |
| Janssen Biotech, INC. | $177.64 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $167.45 | 2022-2025 | |
| Daiichi Sankyo INC. | $159.02 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $144.47 | 2019-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $140.94 | 2022-2025 | Tecentriq, Tecentriq Hybreza, Gazyva |
| Glaxosmithkline, LLC. | $121.38 | 2022-2025 | Ojjaara, Blenrep |
| Apellis Pharmaceuticals, INC. | $97.09 | 2022-2024 | Empaveli |
| Sanofi-Aventis U.S. LLC | $95.95 | 2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Sarhill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.